Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Increases By 498.6%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 43,100 shares, a growth of 498.6% from the February 13th total of 7,200 shares. Based on an average daily trading volume, of 196,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are short sold.

Chugai Pharmaceutical Trading Up 2.9 %

Chugai Pharmaceutical stock opened at $23.56 on Thursday. The firm has a market capitalization of $77.54 billion, a price-to-earnings ratio of 30.60 and a beta of 0.77. Chugai Pharmaceutical has a 1-year low of $14.52 and a 1-year high of $27.19. The firm has a 50 day simple moving average of $22.77 and a 200 day simple moving average of $22.99.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities research analysts forecast that Chugai Pharmaceutical will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.